Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

SinocellTech Closes $181 Million IPO on STAR Board; Triples in Initial Trading

publication date: Jun 22, 2020

Beijing's SinocellTech completed a $181 million IPO on Shanghai's STAR Board and nearly tripled in price during its initial trading session. The offering was priced at 25.64 RMB per share and ended its first session at 73.07 RMB, giving SinocellTech a market capitalization of nearly $4.5 billion. Sinocelltech is a biotech company that discovers and develops mAbs, recombinant proteins and vaccine products. The company has 23 products in its pipeline, including 21 novel differentiated drugs and two biosimilars. More details....

Stock Symbol: (SHA: 688520)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020